vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
vTv Therapeutics confirmed it expects to complete enrollment in the Phase 3 CATT1 trial of cadisegliatin for type 1 diabetes in Q3 2026, with a Phase 2a hybrid closed-loop trial initiating before year-end. The company reported $86.6 million in cash as of June 30, 2026, sufficient to fund operations through the anticipated topline data readout.
Key figures
- Ga expenses
- 5160000
- Rd expenses
- 8770000
- Cash position
- 86643000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.